Literature DB >> 14764126

Expression of vascular endothelial growth factor protein in human renal cell carcinoma.

J Jacobsen1, K Grankvist, T Rasmuson, A Bergh, G Landberg, B Ljungberg.   

Abstract

OBJECTIVE: To evaluate the effect of vascular endothelial growth factor (VEGF, one of the most important angiogenetic factors) in renal cell carcinoma (RCC) by analysing many RCCs for the expression of immunohistochemical (IHC) VEGF-staining related to clinicopathological findings and survival. PATIENTS AND METHODS: VEGF immunostaining was examined with the tissue microarray (TMA) method on tumour samples from 229 patients and validated in 71 by ordinary tissue sections (TS). IHC VEGF expression was quantified by estimating the volume density and staining intensity on a three-grade scale.
RESULTS: In most RCCs there was VEGF staining in the cell cytoplasm and membrane. In cell membranes the VEGF expression declined with storage time. IHC VEGF expression analysed by TMA and TS gave corresponding results. There was no difference in VEGF expression among conventional, papillary and chromophobe RCCs. There were significant correlations between VEGF expression and tumour size and stage. In univariate analysis VEGF expression correlated with survival, especially in conventional RCCs; this prognostic information was lost in multivariate analysis. The VEGF staining intensity correlated only with VEGF expression but not with any clinicopathological factors.
CONCLUSIONS: VEGF protein was present in most RCC cells. There was no difference in VEGF expression among the different RCC types. The correlation between VEGF expression and tumour stage and with prognosis indicates the significance of VEGF within tumour growth and progression in RCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764126     DOI: 10.1111/j.1464-410x.2004.04605.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  50 in total

1.  Advances in cancer tissue microarray technology: Towards improved understanding and diagnostics.

Authors:  Wenjin Chen; David J Foran
Journal:  Anal Chim Acta       Date:  2006-01-23       Impact factor: 6.558

2.  Systemic therapy for metastatic renal cell carcinoma: a review and update.

Authors:  Joshua E Logan; Edward N Rampersaud; Geoffrey A Sonn; Karim Chamie; Arie S Belldegrun; Allan J Pantuck; Dennis J Slamon; Fairooz F Kabbinavar
Journal:  Rev Urol       Date:  2012

3.  Pre-clinical longitudinal monitoring of hemodynamic response to anti-vascular chemotherapy by hybrid diffuse optics.

Authors:  Parisa Farzam; Johannes Johansson; Miguel Mireles; Gabriela Jiménez-Valerio; Mar Martínez-Lozano; Regine Choe; Oriol Casanovas; Turgut Durduran
Journal:  Biomed Opt Express       Date:  2017-04-19       Impact factor: 3.732

Review 4.  Prognostic factors in renal cell carcinoma.

Authors:  Alessandro Volpe; Jean Jacques Patard
Journal:  World J Urol       Date:  2010-04-03       Impact factor: 4.226

5.  Inverse association between programmed death ligand 1 and genes in the VEGF pathway in primary clear cell renal cell carcinoma.

Authors:  Richard W Joseph; Mansi Parasramka; Jeanette E Eckel-Passow; Dan Serie; Kevin Wu; Liuyan Jiang; Krishna Kalari; R Houston Thompson; Thai Huu Ho; Erik P Castle; John Cheville; Eugene D Kwon; E Aubrey Thompson; Alexander Parker
Journal:  Cancer Immunol Res       Date:  2013-08-29       Impact factor: 11.151

Review 6.  Molecular biology of renal cell carcinoma.

Authors:  Begoña Mellado; Pere Gascón
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

Review 7.  Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors.

Authors:  Vitaly Margulis; Christopher G Wood; Eric Jonasch; Surena F Matin
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

8.  Combined use of COX-1 and VEGF immunohistochemistry refines the histopathologic prognosis of renal cell carcinoma.

Authors:  Wesam M Osman; Nermeen S Youssef
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

9.  Targeted therapies in the management of renal cell carcinoma: role of bevacizumab.

Authors:  Bernard Escudier; Jan Cosaert; Sangeeta Jethwa
Journal:  Biologics       Date:  2008-09

10.  Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.

Authors:  J-J Patard; N Rioux-Leclercq; D Masson; S Zerrouki; F Jouan; N Collet; C Dubourg; B Lobel; M Denis; P Fergelot
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.